On December 29, senxuan Pharmaceutical (830946), a listed company on the Beijing stock exchange, climbed the dragon and tiger list with an increase of 29.96%, closing at 14.49 yuan / share, with a record share price.
rose 29.96% to the dragon and tiger list
At 2:46 p.m. on December 29, senxuan pharmaceutical touched the daily limit after rising all the way, and closed at the daily limit price of 14.49 yuan / share, with a turnover rate of 27.7%. According to the data of the dragon and tiger list, 22.5031 million shares were traded on December 29, with a turnover of 283 million yuan. The top 5 buyers are Caitong Securities Co.Ltd(601108) Yiwu Jiangbin West Road Securities Business Department, with a purchase amount of 14.3354 million yuan; Zhongzhong fortune Jining Huancheng West Road Securities Business Department, with a purchase amount of 13.5604 million yuan; Huaxi Securities Co.Ltd(002926) Changchun Qianjin Street securities business department, with a purchase amount of 10.7226 million yuan; Northeast Securities Co.Ltd(000686) Hangzhou Xinbei Road Securities Business Department, with a purchase amount of 5.1618 million yuan; East Money Information Co.Ltd(300059) the second securities business of Tuanjie road in Lhasa, with a purchase amount of 4.9465 million yuan.
The top five sellers’ seats are East Money Information Co.Ltd(300059) the second securities business department of Lhasa East Ring Road, with a sales amount of 5.6137 million yuan; Datong securities Yangquan Taobei middle street business department, with a sales amount of 4.672 million yuan; Shenwan Hongyuan Group Co.Ltd(000166) securities business department, Zhongshan South 1st Road, Huangpu District, Shanghai, with a sales amount of 3606900 yuan; Everbright Securities Company Limited(601788) Ningbo Xiaowen Street business department, with a sales amount of 3.2883 million yuan; Anxin securities Shantou Honglingjin Road Securities Business Department sold 3.2864 million yuan. The total purchase amount of the top five buyers and the top five sellers reached 52.1501 million yuan, with a net purchase amount of 29.6023 million yuan.
in the hot plate, the four-day increase exceeded 90%
Senxuan pharmaceutical’s main business is the R & D, production and sales of APIs, pharmaceutical intermediates and oxygen-containing heterocyclic chemical intermediates. It has 19 kinds of Chinese api registration approval documents, of which 10 kinds of API have obtained Chinese GMP certification qualification, 5 kinds of API have obtained EU CEP certification qualification, 2 kinds of API have obtained Australian GMP certification qualification, 4 kinds of API products have obtained American DMF registration documents, and 1 kind of API product has obtained American VMF registration documents. The company has passed the FDA on-site inspection and is exported to Europe, America and Asia.
In the first three quarters of this year, the company achieved a revenue of 398 million yuan, a year-on-year decrease of 2.62%; The net profit was 98.3862 million yuan, a year-on-year decrease of 9.75%. In the third quarter, the company achieved a revenue of 134 million yuan, a year-on-year increase of 2.79%; The net profit was 22.3748 million yuan, a year-on-year decrease of 42.28%. The decline in performance was mainly due to the increase of operating cost by 18.349 million yuan and the decrease of gross profit by 14.7011 million yuan due to the sharp increase of raw materials on the basis of basically flat income in the third quarter.
In terms of news, on December 28, the “14th five year plan” for the development of medical equipment industry was released. By 2025, the level of advanced foundation and industrial chain modernization of medical equipment industry will be significantly improved, and a comprehensive support capacity for public health and medical health needs will be initially formed. By 2035, the R & D, manufacturing and application of medical equipment will be upgraded to the world advanced level.
Affected by this, the pharmaceutical and medical sector continued to be active. On December 29, Zhejiang Canaan Technology Limited(300412) , Youngy Health Co.Ltd(300247) , Andon Health Co.Ltd(002432) rose by more than 9%, such as Maider Medical Industry Equipment Co.Ltd(688310) , Innovation Medical Management Co.Ltd(002173) , Guangzhou Improve Medical Instruments Co.Ltd(300030) .
In addition, recently, Pfizer covid-19 oral drug paxlovid was authorized by FDA for emergency use. Its main components include ritonavir, while senxuan pharmaceutical products include ritonavir intermediates. Stimulated by this positive, senxuan medicine has risen 91.16% since December 24, of which the deviation from the closing price on December 24 and December 25 has reached 43.02%, ranking the first in the two trading days, and reaching the situation of abnormal trading fluctuation of stocks.
(Volkswagen Securities Journal)
